Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families

Siobhan S. Wahlberg, James Schmeits, George Thomas, Massimo Loda, Judy Garber, Sapna Syngal, Richard D. Kolodner, Edward Fox

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Forty-eight hereditary nonpolyposis colorectal carcinoma (HNPCC) families for which a tumor sample was available were evaluated for the presence of germ-line mutations in MSH2 and MLH1, tumor microsatellite instability (MSI), and where possible, expression of MSH2 and MLH1 in tumors by immunohistochemistry. Fourteen of 48 of the families had a germ-line mutation in either MSH2 or MLH1 that could be detected by genomic DNA sequencing, and 28 of 48 of the families had MSI-H tumors. Four additional families showed loss of expression of MSH2, and one additional family showed loss of expression of MLH1 but did not have germ-line mutations in MSH2 or MLH1 that could be detected by DNA sequencing. MSI-H, as defined using the National Cancer Institute recommended five-microsatellite panel, had a 100% sensitivity for identifying samples having MSH2 or MLH1 mutations or loss of expression. In contrast, loss of MSH2 and MLH1 expression did not identify all samples having germ-line mutations in MSH2 or MLH1, because in five cases, a mutant protein product was expressed that could be detected by IHC. A combination of the Bethesda criteria for HNPCC and an MSI-H phenotype defined the smallest number of cases having all of the germ-line MSH2 and MLH1 mutations that could be detected by DNA sequencing.

Original languageEnglish (US)
Pages (from-to)3485-3492
Number of pages8
JournalCancer Research
Volume62
Issue number12
StatePublished - Jun 15 2002
Externally publishedYes

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Microsatellite Instability
Germ-Line Mutation
Germ Cells
Immunohistochemistry
DNA Sequence Analysis
Mutation
Colorectal Neoplasms
Neoplasms
National Cancer Institute (U.S.)
Mutant Proteins
Microsatellite Repeats
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. / Wahlberg, Siobhan S.; Schmeits, James; Thomas, George; Loda, Massimo; Garber, Judy; Syngal, Sapna; Kolodner, Richard D.; Fox, Edward.

In: Cancer Research, Vol. 62, No. 12, 15.06.2002, p. 3485-3492.

Research output: Contribution to journalArticle

Wahlberg, Siobhan S. ; Schmeits, James ; Thomas, George ; Loda, Massimo ; Garber, Judy ; Syngal, Sapna ; Kolodner, Richard D. ; Fox, Edward. / Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. In: Cancer Research. 2002 ; Vol. 62, No. 12. pp. 3485-3492.
@article{6617102f69ec44b3be91a3538eb166bd,
title = "Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families",
abstract = "Forty-eight hereditary nonpolyposis colorectal carcinoma (HNPCC) families for which a tumor sample was available were evaluated for the presence of germ-line mutations in MSH2 and MLH1, tumor microsatellite instability (MSI), and where possible, expression of MSH2 and MLH1 in tumors by immunohistochemistry. Fourteen of 48 of the families had a germ-line mutation in either MSH2 or MLH1 that could be detected by genomic DNA sequencing, and 28 of 48 of the families had MSI-H tumors. Four additional families showed loss of expression of MSH2, and one additional family showed loss of expression of MLH1 but did not have germ-line mutations in MSH2 or MLH1 that could be detected by DNA sequencing. MSI-H, as defined using the National Cancer Institute recommended five-microsatellite panel, had a 100{\%} sensitivity for identifying samples having MSH2 or MLH1 mutations or loss of expression. In contrast, loss of MSH2 and MLH1 expression did not identify all samples having germ-line mutations in MSH2 or MLH1, because in five cases, a mutant protein product was expressed that could be detected by IHC. A combination of the Bethesda criteria for HNPCC and an MSI-H phenotype defined the smallest number of cases having all of the germ-line MSH2 and MLH1 mutations that could be detected by DNA sequencing.",
author = "Wahlberg, {Siobhan S.} and James Schmeits and George Thomas and Massimo Loda and Judy Garber and Sapna Syngal and Kolodner, {Richard D.} and Edward Fox",
year = "2002",
month = "6",
day = "15",
language = "English (US)",
volume = "62",
pages = "3485--3492",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families

AU - Wahlberg, Siobhan S.

AU - Schmeits, James

AU - Thomas, George

AU - Loda, Massimo

AU - Garber, Judy

AU - Syngal, Sapna

AU - Kolodner, Richard D.

AU - Fox, Edward

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Forty-eight hereditary nonpolyposis colorectal carcinoma (HNPCC) families for which a tumor sample was available were evaluated for the presence of germ-line mutations in MSH2 and MLH1, tumor microsatellite instability (MSI), and where possible, expression of MSH2 and MLH1 in tumors by immunohistochemistry. Fourteen of 48 of the families had a germ-line mutation in either MSH2 or MLH1 that could be detected by genomic DNA sequencing, and 28 of 48 of the families had MSI-H tumors. Four additional families showed loss of expression of MSH2, and one additional family showed loss of expression of MLH1 but did not have germ-line mutations in MSH2 or MLH1 that could be detected by DNA sequencing. MSI-H, as defined using the National Cancer Institute recommended five-microsatellite panel, had a 100% sensitivity for identifying samples having MSH2 or MLH1 mutations or loss of expression. In contrast, loss of MSH2 and MLH1 expression did not identify all samples having germ-line mutations in MSH2 or MLH1, because in five cases, a mutant protein product was expressed that could be detected by IHC. A combination of the Bethesda criteria for HNPCC and an MSI-H phenotype defined the smallest number of cases having all of the germ-line MSH2 and MLH1 mutations that could be detected by DNA sequencing.

AB - Forty-eight hereditary nonpolyposis colorectal carcinoma (HNPCC) families for which a tumor sample was available were evaluated for the presence of germ-line mutations in MSH2 and MLH1, tumor microsatellite instability (MSI), and where possible, expression of MSH2 and MLH1 in tumors by immunohistochemistry. Fourteen of 48 of the families had a germ-line mutation in either MSH2 or MLH1 that could be detected by genomic DNA sequencing, and 28 of 48 of the families had MSI-H tumors. Four additional families showed loss of expression of MSH2, and one additional family showed loss of expression of MLH1 but did not have germ-line mutations in MSH2 or MLH1 that could be detected by DNA sequencing. MSI-H, as defined using the National Cancer Institute recommended five-microsatellite panel, had a 100% sensitivity for identifying samples having MSH2 or MLH1 mutations or loss of expression. In contrast, loss of MSH2 and MLH1 expression did not identify all samples having germ-line mutations in MSH2 or MLH1, because in five cases, a mutant protein product was expressed that could be detected by IHC. A combination of the Bethesda criteria for HNPCC and an MSI-H phenotype defined the smallest number of cases having all of the germ-line MSH2 and MLH1 mutations that could be detected by DNA sequencing.

UR - http://www.scopus.com/inward/record.url?scp=0037096801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037096801&partnerID=8YFLogxK

M3 - Article

C2 - 12067992

AN - SCOPUS:0037096801

VL - 62

SP - 3485

EP - 3492

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -